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Summary
 
Paired immunoglobulin-like receptor B (PIR-B) (p91) molecule has been proposed to func-
tion as an inhibitory receptor in B cells and myeloid lineage cells. We demonstrate here that
the cytoplasmic region of PIR-B is capable of inhibiting B cell activation. Mutational analysis
of five cytoplasmic tyrosines indicate that tyrosine 771 in the motif VxYxxL plays the most
crucial role in mediating the inhibitory signal. PIR-B–mediated inhibition was markedly re-
duced in the SH2-containing protein tyrosine phosphatases SHP-1 and SHP-2 double-defi-
cient DT40 B cells, whereas this inhibition was unaffected in the inositol polyphosphate
5
 
9
 
-phosphatase SHIP-deficient cells. These data demonstrate that PIR-B can negatively regu-
late B cell receptor activation and that this PIR-B–mediated inhibition requires redundant
functions of SHP-1 and SHP-2.
 
T
 
he ability of B cells to respond to antigen relies on sig-
nals transmitted through the B cell antigen receptor
(BCR) complex. Activation of cytoplasmic protein ty-
rosine kinases is the earliest measurable biochemical re-
sponse to BCR cross-linking. This initial event leads to the
generation of secondary signals including Ras activation,
phosphatidylinositol 3-kinase activation, turnover of phos-
phoinositides, and calcium mobilization. Both the strength
and duration of the BCR-elicited signal are important in
directing biological responses of B cells such as prolifera-
tion, differentiation, and apoptosis (for reviews see refer-
ences 1–4). Thus, attenuation and termination of these ac-
tivation signals are also critical components for B cell
response.
B cell activation is inhibited by cross-linking Fc
 
g
 
RIIB
with the BCR (5, 6). The cytoplasmic domain of Fc
 
g
 
RIIB
contains an immunoreceptor tyrosine-based inhibitory mo-
tif (ITIM), which is necessary for the inhibitory function of
the receptor (7, 8). Phosphorylation of the tyrosine in the
ITIM by an activated protein tyrosine kinase(s) is critical to
its inhibitory mechanism (7). Although the phosphorylated
Fc
 
g
 
RIIB ITIM associates with the SH2-containing protein
tyrosine phosphatase SHP-1 and the SH2-containing inosi-
tol polyphosphate 5
 
9
 
-phosphatase SHIP (9, 10), functional
evidence has shown that inhibition by Fc
 
g
 
RIIB primarily
involves SHIP (11–13). In B cells, in addition to Fc
 
g
 
RIIB,
a recently cloned p91 (PIR-B) is suggested to function as
an inhibitory receptor. PIR-B, a member of the immuno-
globulin superfamily, is a 91-kD transmembrane glycopro-
tein containing four potential ITIMs in its cytoplasmic re-
gion (14, 15).
A growing family of inhibitory receptors that can inter-
rupt the activation process have generated interest in the
mechanism of inhibition and raised questions about the
similarity in this mechanism used by the different receptors.
To test whether PIR-B can deliver inhibitory signals in B
cells, and whether both PIR-B– and Fc
 
g
 
RIIB-mediated
inhibitory responses are dependent on the same signaling
molecule SHIP, we have constructed chimeric Fc
 
g
 
RIIB–
PIR-B molecules with the cytoplasmic region of PIR-B
and assessed their ability to inhibit BCR signaling. We report
here that SHP-1 and SHP-2, but not SHIP, are required
for PIR-B–mediated inhibitory signal.
 
Materials and Methods
 
Cells, Expression Construct, and Abs.
 
Various mutant DT40 cells,
wild-type A20, and A20 IIA1.6 cells were maintained in RPMI
1640 supplemented with 10% FCS, penicillin, streptomycin, and
glutamine. Fc
 
g
 
RIIB–PIR-B chimera and its mutants were cre-
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ated by the PCR method. Resulting constructs were confirmed
by DNA sequencing. The mutant and wild-type Fc
 
g
 
RIIB–PIR-B
cDNAs were subcloned into pApuro vector (16) and were elec-
troporated into DT40 or A20 IIA1.6 cells as previously described
(17). After selecting clones in the presence of puromycin (0.5 
 
m
 
g/
ml), cell surface expression levels of Fc
 
g
 
RIIB–PIR-B were
checked by flow cytometry analysis using anti–mouse Fc
 
g
 
RIIB
mAb, 2.4G2 (18). Anti–chicken IgM mAb M4, anti-SHIP Ab,
intact rabbit anti–mouse IgM, 
 
F(ab
 
9
 
)
 
2
 
 rabbit anti–mouse IgM,
and antiphosphotyrosine mAb 4G10 were as previously described
(11). Anti–SHP-1 Ab and anti–PIR-B Ab were obtained by im-
munizing rabbits with bacterially expressed glutathione S-trans-
ferase fusion protein containing chicken SHP-1, and peptides in the
mouse PIR-B cytoplasmic region, respectively. Anti–SHP-2 Ab, in-
tact rabbit anti–mouse IgG, and 
 
F(ab
 
9
 
)
 
2
 
 rabbit anti–mouse IgG were
purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA),
Chemicon, Inc. (Temecula, CA), and Chemicon, Inc., respectively.
 
Generation of SHIP-, SHP-1–, SHP-2–, and SHP-1/SHP-2–defi-
cient DT40 Cells.
 
Chicken spleen cDNA library (Clontech, Palo
Alto, CA) was screened by murine SHP-1 cDNA (provided by
Dr. J.N. Ihle, St. Jude Children’s Research Hospital, Memphis,
TN) (19). Using the isolated chicken SHP-1 cDNA, the chicken
genomic DNA library (Clontech) was screened to obtain genomic
clones. After subcloning, the 
 
neo
 
- or 
 
his
 
-targeting constructs were
made by replacing the genomic fragment containing exons corre-
sponding to SHP-1 amino acid residues 420–520 with 
 
neo 
 
or 
 
his
 
cassette. These constructs were sequentially transfected into wild-
type DT40 cells by electroporation to obtain null mutants. Selection
for drug-resistant clones was carried out by using G418 (2 mg/ml)
and histidinol (1 mg/ml). Based on a previously published se-
quence of chicken SHP-2 (20), chicken SHP-2 cDNA and ge-
nomic clones were obtained by the PCR method. The targeting
vectors, pSHP-2–bsr, pSHP-2–hisD, and pSHP-2–hygro were
constructed by replacing the genomic fragment-containing exons
that correspond to SHP-2 amino acid residues 472–533 with 
 
bsr
 
,
 
hisD
 
, or 
 
hygro 
 
cassette. The targeting vector pSHP-2–bsr was lin-
earized and introduced into wild-type DT40 cells. Selection was
done in the presence of 50 
 
m
 
g/ml blasticidin S. Clones were
screened by Southern blot analysis. pSHP-2–hisD was transfected
into the 
 
bsr-
 
targeted clone and selected with both blasticidin S (50
 
m
 
g/ml) and histidinol (1 mg/ml). For the generation of SHP-1/
SHP-2 double-deficient DT40 cells, the targeting vectors pSHP-
2–bsr and pSHP-2–hygro were sequentially transfected into
SHP-1–deficient cells (11). Clones were selected in the presence
of 50 
 
m
 
g/ml blasticidin S and 1.6 mg/ml hygromycin. The pro-
cedures to establish SHIP-deficient DT40 cells were described in
reference 11. Evidence for null mutants of these knock-out
DT40 cells were demonstrated by Western blotting analysis (see
Fig. 5 
 
A
 
) as well as Northern blotting analysis (data not shown).
 
Immunoprecipitation and Western Blotting Analysis.
 
IIA1.6 transfor-
mants and wild-type A20 cells (2 
 
3 
 
10
 
7
 
) in 1 ml of RPMI 1640
medium were incubated for 3 min at 37
 
8
 
C with intact (50 
 
m
 
g) or
F(ab
 
9
 
)
 
2
 
 fragment (25 
 
m
 
g) of rabbit anti-mouse IgG. Cells were
solubilized in lysis buffer (1% NP-40, 150 mM NaCl, 20 mM
Tris, pH 7.5, 1 mM EDTA, 10% glycerol) containing 50 mM
NaF, 10 
 
m
 
M molybdate, 2 mM sodium vanadate supplemented
with protease inhibitors as previously described (17). Precleared
lysates were sequentially incubated with 2.4G2 and anti–rat IgG-
agarose. Immunoprecipitates were separated by SDS-PAGE gel,
transferred to nitrocellulose membrane, and detected by appropriate
Abs and ECL system (Amersham Corp., Arlington Heights, IL).
 
Calcium measurements.
 
Cells (5 
 
3 
 
10
 
6
 
) were suspended in PBS
containing 20 mM Hepes (pH 7.2), 5 mM glucose, 0.025% BSA,
and 1 mM CaCl
 
2
 
, and loaded with 3 
 
m
 
M Fura-2/AM at 37
 
8
 
C for
45 min. Cells were washed twice, and adjusted to 10
 
6
 
 cells/ml.
Continuous monitoring of fluorescence from the cell suspension
was performed using Hitachi F-2000 fluorescence spectropho-
tometer (Hitachi Limited, Tokyo, Japan) at an excitation wave-
length of 340 nm and an emission wavelength of 510 nm. Cali-
bration and calculation of calcium levels were done as previously
described (21). IIA1.6 cells expressing Fc
 
g
 
RIIB–PIR-B cells were
stimulated by adding intact or F(ab
 
9
 
)
 
2
 
 fragment of rabbit anti–mouse
IgG, resulting in coligation of BCR to chimeric Fc
 
g
 
RIIB–PIR-B
receptor or cross-linking BCR alone. Stimulation of DT40 cells
was carried out by adding intact or F(ab
 
9
 
)
 
2
 
 fragment of rabbit
anti–mouse IgM followed by the anti–chicken IgM mAb, M4.
Two independent IIA1.6 transformants expressing each Fc
 
g
 
RIIB–
PIR-B mutant were used for calcium measurement. In the case of
DT40 cells expressing Fc
 
g
 
RIIB–PIR-B, three different clones
were used for this analysis. Calcium release from intracellular cal-
cium store was measured in the buffer containing 1 mM EGTA.
 
Nuclear Factor in Activated T Cell Luciferase Assays.
 
24 h after
transfection with 20 
 
m
 
g of nuclear factor in activated T cell (NF-
AT) (Renilla luciferase control reporter vector) luciferase reporter
gene and 2 
 
m
 
g of pRL-CMV (Promega, Madison, WI), 2 
 
3 
 
10
 
5
 
transfected cells were aliquoted into a 96-well plate and cultured
in a final volume of 100 
 
m
 
l of RPMI 1640 medium. Cells were
stimulated as previously described (11). After 5 h of stimulation,
cells were lysed and luciferase activity was measured with the
Dual-luciferase reporter assay system (Promega).
 
Flow Cytometric Analysis for Surface Expression of Fc
 
g
 
RIIB–PIR-B.
 
Cells were washed, stained with FITC-conjugated 2.4G2 (Phar-
Mingen, San Diego, CA), and analyzed by FACScan
 
Ò
 
 (Becton
Dickinson, Mountain View, CA). The x and y axes for the histo-
grams in inset boxes (Fig. 2 
 
A
 
, 4 
 
A
 
, and 5 
 
B
 
) indicate fluorescence
intensity (4-decade-log scales) and relative cell number, respec-
tively. 
 
Results and Discussion
 
The Cytoplasmic Domain of PIR-B Is Capable of Inhibiting
BCR Activation.
 
To test whether the cytoplasmic domain
of PIR-B may inhibit BCR activation, a chimeric mole-
cule with the cytoplasmic domain of PIR-B and the extra-
cellular domain of Fc
 
g
 
RIIB was constructed (Fig. 1). This
molecule was transfected into the Fc
 
g
 
RIIB-negative mu-
tant of the mouse A20 B cell lymphoma IIA1.6 (22) to ob-
tain stable transformants. Expression level of this chimeric
receptor was assessed by flow cytometry analysis using anti–
mouse Fc
 
g
 
RIIB mAb, 2.4G2 (Fig. 2 
 
A
 
). IIA1.6 cells ex-
pressing the Fc
 
g
 
RIIB–PIR-B receptor was stimulated by
BCR cross-linking alone (Fig. 2 
 
A
 
, 
 
solid line
 
) or coligation
of BCR and the Fc
 
g
 
RIIB–PIR-B (Fig. 2 
 
A
 
, 
 
dashed line
 
).
Coligation of Fc
 
g
 
RIIB–PIR-B to the BCR resulted in an
inhibition of intracellular free calcium. Incubation with
EGTA further decreased Ca
 
2
 
1
 
 mobilization upon co–cross-
linking of BCR with Fc
 
g
 
RIIB–PIR-B, indicating that the
Fc
 
g
 
RIIB–PIR-B acts at least on calcium release from intra-
cellular stores. Consistent with these results, transcriptional
activation of the NF-AT luciferase reporter was inhibited
by coligation of the BCR to this chimeric molecule (Fig. 2 
 
B
 
).
Thus, the cytoplasmic domain of PIR-B can deliver a sig-
nal that inhibits BCR-mediated function in IIA1.6 B cells. 
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SHP-1 and SHP-2 Associate with the Cytoplasmic Domain
of PIR-B.
 
The presence of ITIM-related sequences in the
PIR-B cytoplasmic domain (Fig. 1) suggests that the PIR-B
may become tyrosine phosphorylated, resulting in its asso-
ciation with SH2-containing signaling molecules such as
SHP-1, SHP-2, and/or SHIP. Using IIA1.6 cells transfected
with Fc
 
g
 
RIIB–PIR-B, the status of tyrosine phosphorylation
of Fc
 
g
 
RIIB–PIR-B was determined by immunoprecipita-
tion followed by Western blotting with antiphosphoty-
rosine mAb 4G10. As shown in Fig. 3 
 
A
 
, the chimeric re-
ceptor was slightly tyrosine phosphorylated upon BCR
cross-linking alone and this phosphorylation was markedly
augmented by coligation of BCR and Fc
 
g
 
RIIB–PIR-B.
The Fc
 
g
 
RIIB–PIR-B phosphorylation was due to tyrosine
residues located in the cytoplasmic domain of PIR-B, since
Fc
 
g
 
RIIB–PIR-B(Y/F) (Fig. 1) did not undergo tyrosine
phosphorylation upon coligation of BCR and Fc
 
g
 
RIIB–
PIR-B(Y/F) (data not shown). After co–cross-linking of
BCR with Fc
 
g
 
RIIB–PIR-B, the chimeric molecule was
immunoprecipitated followed by Western blotting with
anti–SHP-1 or anti–SHP-2 Ab (Fig. 3 
 
B
 
, 
 
middle
 
 and 
 
right
 
),
demonstrating that SHP-1 and SHP-2 are recruited to Fc
 
g-
RIIB–PIR-B. In contrast, recruitment of SHIP to Fcg-
RIIB–PIR-B could not be detected (Fig. 3 B, left, lanes 1–3).
Figure 1. Schematic diagram of FcgRIIB–PIR-B chimeric molecules.
PIR-B cytoplasmic region contains four ITIM-like motifs (residues 688–
693, SLYASV; 717–722, ETYAQV; 769–774, VTYAQL; and 799–804,
SVYATL). In addition to these tyrosines, the cytoplasmic domain of
PIR-B contains one more tyrosine (residue 747). The open and shaded
boxes represent portions of FcgRIIB and PIR-B, respectively.
Figure 2. Inhibition of BCR-mediated cell activation by FcgRIIB–
PIR-B. (A) Calcium mobilization stimulated by BCR cross-linking (solid
line) and coligation of BCR to FcgRIIB–PIR-B (dashed line) in IIA1.6
cells expressing wild-type FcgRIIB–PIR-B. Calcium release from intra-
cellular calcium store was measured in the presence of 1 mM EGTA,
shown by right panel. Histogram in the inset box indicates the expression
level of FcgRIIB–PIR-B by 2.4G2 staining. Unstained cells were used as
a negative control (open histogram). Stimulation of FcgRIIB–PIR-B alone
by 2.4G2 did not induce calcium mobilization. (B) NF-AT activation by
BCR cross-linking and the coligation of BCR to FcgRIIB–PIR-B. The
results are shown as relative NF-AT activity to BCR cross-linking alone.
Figure 3. Recruitment of SHP-1 and SHP-2 to FcgRIIB–PIR-B after
coligation of BCR and the chimeric receptor. (A) Tyrosine phosphoryla-
tion of FcgRIIB–PIR-B by BCR cross-linking and coligation of BCR to
FcgRIIB–PIR-B. IIA1.6 cells expressing wild-type FcgRIIB–PIR-B
were incubated with F(ab9)2 rabbit anti–mouse IgG, or with intact rabbit
anti–mouse IgG. FcgRIIB–PIR-B was then immunoprecipitated with
2.4G2, separated by SDS-PAGE gel, transferred to membrane, and im-
munoblotted with antiphosphotyrosine mAb 4G10 (top). The same mem-
brane was reprobed with anti–PIR-B Ab (bottom). (B) Immunoblotting
with anti–SHP-1 and anti–SHP-2 Abs after BCR cross-linking and the
coligation of BCR to FcgRIIB–PIR-B. IIA1.6 cells expressing wild-type
FcgRIIB–PIR-B were stimulated with either F(ab9)2 rabbit anti–mouse
IgG or intact rabbit anti–mouse IgG and were lysed. FcgRIIB–PIR-B
was then immunoprecipitated with 2.4G2, resolved by SDS-PAGE gel,
transferred to membrane, and probed with anti–SHP-1 or anti–SHP-2
Ab. In the case of immunoblotting with anti-SHIP, in addition to IIA1.6
cells expressing wild-type FcgRIIB–PIR-B (lanes 1–3), wild-type A20
cells expressing FcgRIIB were stimulated similarly (lanes 4–6). FcgRIIB–
PIR-B or FcgRIIB was immunoprecipitated with 2.4G2 followed by
Western blotting with anti-SHIP Ab. Membranes were reprobed with
anti–PIR-B Ab (bottom).1358 PIR-B–mediated Inhibitory Signal on B Cell
As a positive control, recruitment of SHIP to phosphory-
lated FcgRIIB molecule was clearly observed under the
same experimental conditions (Fig. 3 B, left, lanes 4–6).
Tyrosine 771 in the Cytoplasmic Domain of PIR-B Is Essen-
tial for Inhibition. The cytoplasmic tail of PIR-B contains
four copies (residues 688–693, 717–722, 769–774, and
799–804) of potential ITIMs (14, 15, 23). The inhibition
assay described above allowed us to assess the structural im-
portance of each phosphotyrosine for the inhibitory signal.
Various tyrosine mutants were made (Fig. 1) and trans-
fected into IIA1.6 cells to obtain stable transformants.
IIA1.6 cells expressing comparable levels of chimeric re-
ceptors (Fig. 4 A) were stimulated by BCR alone or coliga-
tion of BCR and the chimeric mutants. FcgRIIB–PIR-
B(Y/F) almost reverted the inhibitory effect of PIR-B.
This result demonstrates that phosphorylation of cytoplas-
mic tyrosines of PIR-B plays an important role in the in-
hibitory signal and that the residual inhibition may be inde-
pendent of tyrosine phosphorylation on PIR-B (Fig. 4 B).
Similar to FcgRIIB–PIR-B(Y/F), inhibition of the BCR-
induced calcium mobilization was almost abrogated by
coligating of BCR and FcgRIIB–PIR-B(Y771, 801F). Anal-
ysis of the single tyrosine mutants, FcgRIIB–PIR-B(Y771F)
and FcgRIIB–PIR-B(Y801F), indicates that these tyrosines
have different degrees of importance in the inhibitory signal
mediated by FcgRIIB–PIR-B. FcgRIIB–PIR-B(Y801F) in-
hibited calcium mobilization to a lesser degree than did
wild-type chimeric receptor, whereas the FcgRIIB–PIR-
B(Y771F) mutant inhibited it to a much lesser degree than
wild-type FcgRIIB–PIR-B (Fig. 4, A and B). Thus, these
data indicate that both tyrosines contribute to the inhibi-
tory effect and that tyrosine 771 plays a more critical role in
inhibiting the BCR-induced calcium mobilization.
SHP-1 and SHP-2 Are Redundantly Required for PIR-
B–mediated Inhibition. To test directly the role of SHIP,
SHP-1, and SHP-2 in the inhibitory signal delivered by
PIR-B cytoplasmic tail, B cell lines deficient in SHIP,
SHP-1, or SHP-2 individually and in a combination of
SHP-1 and SHP-2 were established using a chicken DT40
B cell line as a consequence of homologous recombination
(Fig. 5 A). A detailed analysis of BCR signal transduction
in these mutants will be presented elsewhere. FcgRIIB–
PIR-B chimeric molecule was transfected into DT40 wild-
Figure 4. Requirement of cytoplasmic tyrosine residues in inhibitory
response. (A) Calcium mobilization was monitored after BCR cross-link-
ing (solid line) and coligation (dashed line) in IIA1.6 cells expressing various
FcgRIIB–PIR-B mutants. Surface expression levels of FcgRIIB–PIR-B
mutants are indicated in inset boxes. (B) Comparison of inhibitory effect
by various FcgRIIB–PIR-B mutants. The percentage of [Ca21]i was
given by the total calcium mobilization elicited by coligation of BCR to
FcgRIIB–PIR-B over that by BCR stimulation alone. The results are ex-
pressed as the mean from two independent clones.
Figure 5. Reduction of FcgRIIB–PIR-B–mediated inhibitory effect in
SHP-1/SHP-2 double-deficient cells. (A) SHIP, SHP-1, or SHP-2 pro-
tein expression on various gene-targeted DT40 cells. Each protein was
immunoprecipitated and was detected by Western blotting analysis using
anti-SHIP, anti–SHP-1, or anti–SHP-2 Ab. (B) Calcium mobilization
was measured after BCR cross-linking (solid line) and coligation (dashed
line) in various DT40 mutants expressing FcgRIIB–PIR-B. Surface ex-
pression levels of FcgRIIB–PIR-B are indicated in inset boxes. (C) Com-
parison of inhibitory effect in various mutant DT40 cells. The results are
expressed as the mean from three independent clones. Error bars represent
SD from the mean.1359 Maeda et al. Brief Definitive Report
type and mutant cells, and compared for its ability to medi-
ate the inhibitory signaling response. In contrast to IIA1.6
B cells, a more residual inhibition by FcgRIIB–PIR-B(Y/F)
was observed in DT40 cells (Fig. 5, B and C). Various genetic
background DT40 cells expressing similar levels of FcgRIIB–
PIR-B were stimulated with BCR cross-linking alone (Fig.
5, solid line) or coligation of BCR and the FcgRIIB–PIR-B
(dashed line). As shown in Fig. 5 B, FcgRIIB–PIR-B–medi-
ated inhibition of calcium mobilization was unperturbed in
SHIP-deficient DT40 cells, but was substantially reduced
in SHP-1/SHP-2 double-deficient cells. The reduction of
the chimeric receptor-mediated inhibition was also observed
by loss of either SHP-1 or SHP-2 alone. However, this re-
duction was less than that in double-deficient cells. These
results demonstrate that redundant functions of SHP-1 and
SHP-2 are required for the FcgRIIB–PIR-B–mediated in-
hibitory signal.
Signals from the BCR and coreceptors such as CD19,
CD22, and FcgRIIB (24, 25) are integrated inside the cell,
allowing the B cell to mount a response appropriate to the
source of the antigen and the lymphocyte environment. In
this study, we provide evidence that the cytoplasmic region
of PIR-B is capable of inhibiting B cell activation by a
phosphotyrosine-dependent manner in IIA1.6 and DT40 B
cells. Coligation of BCR and FcgRIIB–PIR-B induced ty-
rosine phosphorylation of the cytoplasmic domain of PIR-B
and this phosphorylation was abrogated by the FcgRIIB–
PIR-B(Y/F) mutant. Moreover, this mutant markedly re-
duced the inhibitory effects on BCR signaling, suggesting that
the SH2-containing proteins are involved in PIR-B–medi-
ated inhibitory signals.
The finding that the residual inhibition by FcgRIIB–
PIR-B still occurs in SHP-1 and SHP-2 double-deficient
DT40 cells, implicates that, in addition to SHP-1 and
SHP-2, another SH2-containing protein(s) may participate
in this inhibitory signal to some extent. Nevertheless, the
substantial reduction of the inhibition by loss of SHP-1 and
SHP-2 clearly indicates that the redundant functions of
these SH2-containing phosphatases are required for PIR-
B–mediated inhibition. Supporting this conclusion, both
SHP-1 and SHP-2 were recruited to the phosphorylated
FcgRIIB–PIR-B. In contrast to requirement of SHIP for
an inhibitory response by FcgRIIB, our biochemical and
functional data demonstrate that SHIP is dispensable for the
PIR-B–mediated inhibitory response.
Mutational analysis of five cytoplasmic tyrosines indicates
that tyrosine 771 in the motif VTYAQL plays the most
crucial role in mediating the inhibitory signal and that ty-
rosine 801 in the motif SVYATL also contributes. The more
functional importance of tyrosine 771 may reflect the fact that
the motif surrounding tyrosine 771 matches better with the
consensus I/VxYxxL sequence than that of tyrosine 801
(26). Binding of SH2 domains of SHP-1 and SHP-2 to ty-
rosine phosphorylated PIR-B would serve to relocate
SHP-1 and SHP-2 to membrane (11), where they may gain
access to potential substrates. Simultaneously, these phos-
phatases may be converted to an open conformation by
binding to phosphorylated PIR-B, thereby leading to an in-
crease of their enzymatic activity (27).
The ligand of PIR-B is still unknown. Significant ho-
mology of PIR-B to recently isolated LIR-1 (28), together
with the evidence that LIR-1 is able to bind to the MHC
class I molecule, suggests that PIR-B may be a receptor for
MHC class I or class I–related molecules. Thus, similar to
inhibition of NK cytotoxicity by interaction between class
I molecules on target cells and KIRs on NK cells (29–32),
cell–cell interactions may bring PIR-B into the close prox-
imity of antigen-bound BCR, resulting in attenuation of
BCR signaling. Alternatively, interaction of PIR-B with a
putative ligand may remove it from the vicinity of BCR in
order to release the B cells from the negative regulatory ef-
fects. Identification of the ligand for PIR-B as well as sub-
strates for SHP-1 and SHP-2 will further clarify biological
roles of PIR-B in the immune response and its mechanism
of inhibition.
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